{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Intranasal Esketamine and Dexmedetomidine for Sedation in Toddlers"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "In this prospective, double-blind, randomised controlled trial, 121 children aged 1-3 years scheduled for TTE at Hunan Children's Hospital were enrolled."
      },
      "Participants": {
        "score": 2,
        "evidence": "121 children aged 1-3 years scheduled for TTE at Hunan Children's Hospital were enrolled."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomly assigned to receive dexmedetomidine 1 mcg.kg\u22121 combined with esketamine 0.5 mg.kg\u22121 (group S1), 1 mg.kg\u22121 (group S2), or 1.5 mg.kg\u22121 (group S3)."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to evaluate the efficacy and safety of different doses of intranasal esketamine combined with dexmedetomidine for sedation in toddlers undergoing transthoracic echocardiography (TTE)."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the success rate of sedation, measured within 45 minutes."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed."
      },
      "Blinding": {
        "score": 3,
        "evidence": "Blinding included anesthesiologists, sonographers, children, and parents."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "121 children aged 1-3 years scheduled for TTE at Hunan Children's Hospital were enrolled."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Of the 121 children, 40 were analysed in group S1, 41 in group S2, and 40 in group S3."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "The success rates were 60% in S1, 85.4% in S2, and 87.5% in S3 (p = 0.004)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were minimal, with one case of upper airway obstruction in S3 and four instances of oxygen desaturation, all resolving without intervention."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: ChiCTR2200060976"
      },
      "Funding": {
        "score": 1,
        "evidence": "Supported by the Scientific Research Fund of the Hunan Medical Association and the Scientific Research Project of the Hunan Provincial Health Commission."
      }
    },
    "total_score": 22,
    "max_score": 25
  },
  "model": "gpt-4o"
}